We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra Life Sciences Forges Ahead with Expansion Plans
Read MoreHide Full Article
On Jun 28, we issued an updated research report on the world’s largest manufacturer of regenerative medicines, Integra Life Sciences Holdings Corporation (IART - Free Report) . The stock currently holds a Zacks Rank #2 (Buy).
Keeping in line with its three-pronged strategy, Integra Life Sciences Holdings is presently focusing on investments in innovative products via organic means and geographic expansion outside the U.S.
We are also looking forward to the company’s recent distribution agreement with Vomaris Wound Care, Inc., a company specializing in wound care. As per the deal, Vomaris’ Advanced Microcurrent Technology will complement Integra Life Sciences’ Omnigraft technology, boosting the company’s Orthopedics and Tissue Technologies business.
Meanwhile, with the recent partnership with AlloSource, the largest providers of cartilage, soft-tissue allografts used in surgical procedures, Integra Life Sciences gained entry into Acellular dermal matrices, which will help it to commercialize HuMend by mid-2016 in North America.
Prior to this, the company had entered into an agreement with PREZIO Health, a leading provider of surgical instruments and repair management services. It is expected that this agreement will offer highest quality care to patients at an affordable price.
Notably, the company received FDA approval for its Integra Omnigraft Dermal Regeneration Matrix. Previously, the company’s Integra Dermal Regeneration Template (IDRT) gained FDA approval for the treatment of diabetic foot ulcers (DFU), marking a milestone achievement in the medical technology market.
The company has established a strong presence overseas and has generated solid revenue growth in its Surgical Solutions business, thanks to the MicroFrance buyout and increased uptake of the MAYFIELD2 Cranial stabilization device in Asia Pacific.
The company is currently working on the integration of Salto ankle and has also initiated the controlled market release of the Cadence Total Ankle system. Management expects to gain faster traction overseas by maintaining its focus on Specialty Surgical Solutions and Orthopedics and Tissue Technologies.
However, the company faces challenges such as foreign exchange fluctuations and natural calamities which hinder the ongoing research processes. The company also faces stiff competition in spine market.
Key Picks in the Sector
Some top-ranked stocks in the healthcare sector are Retrophin, Inc. , Heska Corp. and Fibrocell Science, Inc. . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Integra Life Sciences Forges Ahead with Expansion Plans
On Jun 28, we issued an updated research report on the world’s largest manufacturer of regenerative medicines, Integra Life Sciences Holdings Corporation (IART - Free Report) . The stock currently holds a Zacks Rank #2 (Buy).
Keeping in line with its three-pronged strategy, Integra Life Sciences Holdings is presently focusing on investments in innovative products via organic means and geographic expansion outside the U.S.
We are also looking forward to the company’s recent distribution agreement with Vomaris Wound Care, Inc., a company specializing in wound care. As per the deal, Vomaris’ Advanced Microcurrent Technology will complement Integra Life Sciences’ Omnigraft technology, boosting the company’s Orthopedics and Tissue Technologies business.
Meanwhile, with the recent partnership with AlloSource, the largest providers of cartilage, soft-tissue allografts used in surgical procedures, Integra Life Sciences gained entry into Acellular dermal matrices, which will help it to commercialize HuMend by mid-2016 in North America.
Prior to this, the company had entered into an agreement with PREZIO Health, a leading provider of surgical instruments and repair management services. It is expected that this agreement will offer highest quality care to patients at an affordable price.
Notably, the company received FDA approval for its Integra Omnigraft Dermal Regeneration Matrix. Previously, the company’s Integra Dermal Regeneration Template (IDRT) gained FDA approval for the treatment of diabetic foot ulcers (DFU), marking a milestone achievement in the medical technology market.
The company has established a strong presence overseas and has generated solid revenue growth in its Surgical Solutions business, thanks to the MicroFrance buyout and increased uptake of the MAYFIELD2 Cranial stabilization device in Asia Pacific.
The company is currently working on the integration of Salto ankle and has also initiated the controlled market release of the Cadence Total Ankle system. Management expects to gain faster traction overseas by maintaining its focus on Specialty Surgical Solutions and Orthopedics and Tissue Technologies.
However, the company faces challenges such as foreign exchange fluctuations and natural calamities which hinder the ongoing research processes. The company also faces stiff competition in spine market.
Key Picks in the Sector
Some top-ranked stocks in the healthcare sector are Retrophin, Inc. , Heska Corp. and Fibrocell Science, Inc. . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>